Search

Your search keyword '"Chen, Beiyun"' showing total 255 results
Start Over Author "Chen, Beiyun"
255 results on '"Chen, Beiyun"'

2. Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy: Recommendations From the I-SPY Pathology Working Group

Author

Sahoo, Sunati, Krings, Gregor, Chen, Yunn-Yi, Carter, Jodi M., Chen, Beiyun, Guo, Hua, Hibshoosh, Hanina, Reisenbichler, Emily, Fan, Fang, Wei, Shi, Khazai, Laila, Balassanian, Ronald, Klein, Molly E., Shad, Sonal, Venters, Sara J., Borowsky, Alexander D., Symmans, W. Fraser, and Ocal, I. Tolgay

Subjects
Pathology -- Standards, Neoadjuvant therapy -- Patient outcomes, Tumor staging -- Methods -- Standards, Breast cancer -- Prognosis -- Drug therapy -- Patient outcomes, Health
Abstract

* Context.--Neoadjuvant systemic therapy refers to the use of systemic agent(s) for malignancy prior to surgical treatment and has recently emerged as an option for most breast cancer patients eligible for adjuvant systemic therapy. Consequently, treated breast carcinomas have become routine specimens in pathology practices. A standard protocol has not yet been universally adopted for the evaluation and reporting of these specimens. The American Joint Committee on Cancer staging system recognizes the challenges in staging breast carcinomas after neoadjuvant treatment and provides important data points but does not currently provide detailed guidance in estimating the residual tumor burden in the breast and lymph nodes. The Residual Cancer Burden system is the only Web-based system that quantifies treatment response as a continuous variable using residual tumor burden in the breast and the lymph nodes. Objective.--To provide clarifications and guidance for evaluation and reporting of postneoadjuvant breast specimens, discuss issues with the current staging and reporting systems, and provide specific suggestions for future modifications to the American Joint Committee on Cancer system and the Residual Cancer Burden calculator. Data Sources.--English-language literature on the subject and the data from the I-SPy 2, a multicenter, adaptive randomization phase 2 neoadjuvant platform trial for early-stage, high-risk breast cancer patients. Conclusions.--This article highlights challenges in the pathologic evaluation and reporting of treated breast carcinomas and provides recommendations and clarifications for pathologists and clinicians. It also provides specific recommendations for staging and discusses future directions. doi: 10.5858/arpa.2022-0021-EP, Neoadjuvant systemic therapy (NST) in the treatment of breast cancer involves the administration of chemotherapy (NCT) or endocrine therapy prior to definitive surgery. Initially, NCT was implemented as a standard [...]

Published
2023
Full Text
View/download PDF

4. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Author

Adamson, Kathi, Albain, Kathy S., Asare, Adam L., Asare, Smita M., Balassanian, Ron, Beckwith, Heather, Berry, Scott M., Berry, Donald A., Boughey, Judy C., Buxton, Meredith B., Chen, Yunn-Yi, Chen, Beiyun, Chien, A. Jo, Chui, Stephen Y., Clark, Amy S., Clennell, Julia L., Datnow, Brian, DeMichele, Angela M., Duan, Xiuzhen, Edmiston, Kirsten K., Elias, Anthony D., Ellis, Erin D., Esserman, Laura L., Euhus, David M., Fadare, Oluwole, Fan, Fang, Feldman, Michael D, Forero-Torres, Andres, Haley, Barbara B., Han, Hyo S., Harada, Shuko, Haugen, Patricia, Helsten, Teresa, Hirst, Gillian L., Hylton, Nola M., Isaacs, Claudine, Kemmer, Kathleen, Khan, Qamar J., Khazai, Laila, Klein, Molly E., Krings, Gregor, Lang, Julie E., LeBeau, Lauren G., Leyland-Jones, Brian, Liu, Minetta C., Lo, Shelly, Lu, Janice, Magliocco, Anthony, Matthews, Jeffrey B., Melisko, Michelle E., Mhawech-Fauceglia, Paulette, Moulder, Stacy L., Murthy, Rashmi K., Nanda, Rita, Northfelt, Donald W., Ocal, Idris T., Olopade, Olufunmilayo, Pambuccian, Stefan, Paoloni, Melissa, Park, John W., Parker, Barbara A., Perlmutter, Jane, Peterson, Garry, Pusztai, Lajos, Rendi, Mara, Rugo, Hope S., Sahoo, Sunati, Sams, Sharon, Sanil, Ashish, Sattar, Husain, Schwab, Richard B., Singhrao, Ruby, Steeg, Katherine, Stringer-Reasor, Erica, Symmans, W. Fraser, Tawfik, Ossama, Tripathy, Debasish, Troxell, Megan L., van't Veer, Laura J., Venters, Sara J., Vinh, Tuyethoa, Viscusi, Rebecca K., Wallace, Anne M., Wei, Shi, Wilson, Amy, Yau, Christina, Yee, Douglas, Zeck, Jay C., Osdoit, Marie, van der Noordaa, Marieke, Shad, Sonal, Wei, Jane, de Croze, Diane, Hamy, Anne-Sophie, Laé, Marick, Reyal, Fabien, Sonke, Gabe S, Steenbruggen, Tessa G, van Seijen, Maartje, Wesseling, Jelle, Martín, Miguel, del Monte-Millán, Maria, López-Tarruella, Sara, Boughey, Judy C, Goetz, Matthew P, Hoskin, Tanya, Gould, Rebekah, Valero, Vicente, Edge, Stephen B, Abraham, Jean E, Bartlett, John M S, Caldas, Carlos, Dunn, Janet, Earl, Helena, Hayward, Larry, Hiller, Louise, Provenzano, Elena, Sammut, Stephen-John, Thomas, Jeremy S, Cameron, David, Graham, Ashley, Hall, Peter, Mackintosh, Lorna, Godwin, Andrew K, Schwensen, Kelsey, Sharma, Priyanka, DeMichele, Angela M, Cole, Kimberly, Kim, Mi-Ok, van 't Veer, Laura J, Esserman, Laura J, and Symmans, W Fraser

Published
2022
Full Text
View/download PDF

5. HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization

Author

Geiersbach, Katherine B., Sill, Daniel R., Meyer, Reid G., Yuhas, Jason A., Sukov, William R., Mounajjed, Taofic, Carter, Jodi M., Jenkins, Robert B., and Chen, Beiyun

Subjects
Practice guidelines (Medicine), Fluorescence in situ hybridization -- Usage, Health, American Society of Clinical Oncology -- Standards, College of American Pathologists -- Standards
Abstract

* Context.--Guidelines for HER2 testing in breast cancer have changed over time, from the US Food and Drug Administration guideline to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines published in 2007, 2013, and 2018. Objective.--To investigate the change in assignment of HER2 status in breast cancers with equivocal (2+) immunohistochemistry (IHC) results by fluorescence in situ hybridization (FISH) following implementation of the ASCO/CAP 2018 guideline. Design.--The study included 3556 invasive breast cancers that were HER2 equivocal (2+) by IHC and were submitted to our FISH laboratory after July 2018. Reflex testing (with repeat IHC staining) was performed on certain categories of FISH results known as groups 2, 3, and 4. Concomitant review of IHC and FISH was performed on these reflex cases per 2018 guideline recommendations. The FISH data were analyzed to compare US Food and Drug Administration and ASCO/CAP 2007, 2013, and 2018 interpretations. Results.--Of 3548 invasive breast cancers with complete data available, the percentage agreement for FISH according to different guidelines was highest for ASCO/ CAP 2018 versus US Food and Drug Administration (96.5%), followed by ASCO/CAP 2018 versus 2007 (93.8%), and lowest with ASCO/CAP 2018 versus 2013 (83.7%). Per the 2018 guideline, reflex IHC testing was performed on 633 breast cancers (17.8%); the majority of reflex testing results were negative (541 of 633; 85.5%). The overall distribution of HER2 FISH results (per the 2018 guideline) was 88.5% negative and 11.5% positive. Conclusions.--By eliminating the equivocal FISH category, the 2018 ASCO/CAP guideline significantly reduced the HER2 FISH-positive rate in tumors with equivocal (2+) IHC results. (Arch Pathol Lab Med. 2021;145:883-886; doi: 10.5858/arpa.2020-0273-OA), Targeted therapy has had a very favorable impact on survival for patients with HER2-positive breast cancer, and HER2-targeted therapy regimens continue to evolve. Detection of HER2 protein overexpression on the [...]

Published
2021
Full Text
View/download PDF

6. Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)

Author

Haddad, Tufia C., He, Jun, O’Sullivan, Ciara C., Chen, Beiyun, Northfelt, Donald, Dueck, Amylou C., Ballman, Karla V., Tenner, Kathleen S., Linden, Hannah, Sparano, Joseph A., Hopkins, Judith O., De Silva, Chamath, Perez, Edith A., Haluska, Paul, and Goetz, Matthew P.

Published
2021
Full Text
View/download PDF

10. Supplemental Information from IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831

Author

Reinholz, Monica M., primary, Chen, Beiyun, primary, Dueck, Amylou C., primary, Tenner, Kathleen, primary, Ballman, Karla, primary, Riehle, Darren, primary, Jenkins, Robert B., primary, Geiger, Xochiquetzal J., primary, McCullough, Ann E., primary, and Perez, Edith A., primary

Published
2023
Full Text
View/download PDF

11. Data from IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831

Author

Reinholz, Monica M., primary, Chen, Beiyun, primary, Dueck, Amylou C., primary, Tenner, Kathleen, primary, Ballman, Karla, primary, Riehle, Darren, primary, Jenkins, Robert B., primary, Geiger, Xochiquetzal J., primary, McCullough, Ann E., primary, and Perez, Edith A., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Tables 1-5 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Author

Dueck, Amylou C., primary, Reinholz, Monica M., primary, Geiger, Xochiquetzal J., primary, Tenner, Kathleen, primary, Ballman, Karla, primary, Jenkins, Robert B., primary, Riehle, Darren, primary, Chen, Beiyun, primary, McCullough, Ann E., primary, Davidson, Nancy E., primary, Martino, Silvana, primary, Sledge, George W., primary, Kaufman, Peter A., primary, Kutteh, Leila A., primary, Gralow, Julie, primary, Harris, Lyndsay N., primary, Ingle, James N., primary, Lingle, Wilma L., primary, and Perez, Edith A., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 1 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Author

Dueck, Amylou C., primary, Reinholz, Monica M., primary, Geiger, Xochiquetzal J., primary, Tenner, Kathleen, primary, Ballman, Karla, primary, Jenkins, Robert B., primary, Riehle, Darren, primary, Chen, Beiyun, primary, McCullough, Ann E., primary, Davidson, Nancy E., primary, Martino, Silvana, primary, Sledge, George W., primary, Kaufman, Peter A., primary, Kutteh, Leila A., primary, Gralow, Julie, primary, Harris, Lyndsay N., primary, Ingle, James N., primary, Lingle, Wilma L., primary, and Perez, Edith A., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure 2 from Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

Author

Dueck, Amylou C., primary, Reinholz, Monica M., primary, Geiger, Xochiquetzal J., primary, Tenner, Kathleen, primary, Ballman, Karla, primary, Jenkins, Robert B., primary, Riehle, Darren, primary, Chen, Beiyun, primary, McCullough, Ann E., primary, Davidson, Nancy E., primary, Martino, Silvana, primary, Sledge, George W., primary, Kaufman, Peter A., primary, Kutteh, Leila A., primary, Gralow, Julie, primary, Harris, Lyndsay N., primary, Ingle, James N., primary, Lingle, Wilma L., primary, and Perez, Edith A., primary

Published
2023
Full Text
View/download PDF

16. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial

Author

Osdoit, Marie, primary, Yau, Christina, additional, Symmans, W. Fraser, additional, Boughey, Judy C., additional, Ewing, Cheryl A., additional, Balassanian, Ron, additional, Chen, Yunn-Yi, additional, Krings, Gregor, additional, Wallace, Anne M, additional, Zare, Somaye, additional, Fadare, Oluwole, additional, Lancaster, Rachael, additional, Wei, Shi, additional, Godellas, Constantine V., additional, Tang, Ping, additional, Tuttle, Todd M, additional, Klein, Molly, additional, Sahoo, Sunati, additional, Hieken, Tina J., additional, Carter, Jodi M., additional, Chen, Beiyun, additional, Ahrendt, Gretchen, additional, Tchou, Julia, additional, Feldman, Michael, additional, Tousimis, Eleni, additional, Zeck, Jay, additional, Jaskowiak, Nora, additional, Sattar, Husain, additional, Naik, Arpana M., additional, Lee, Marie Catherine, additional, Rosa, Marilin, additional, Khazai, Laila, additional, Rendi, Mara H., additional, Lang, Julie E., additional, Lu, Janice, additional, Tawfik, Ossama, additional, Asare, Smita M., additional, Esserman, Laura J., additional, and Mukhtar, Rita A., additional

Published
2022
Full Text
View/download PDF

19. Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy

Author

Sahoo, Sunati, primary, Krings, Gregor, additional, Chen, Yunn-Yi, additional, Carter, Jodi M., additional, Chen, Beiyun, additional, Guo, Hua, additional, Hibshoosh, Hanina, additional, Reisenbichler, Emily, additional, Fan, Fang, additional, Wei, Shi, additional, Khazai, Laila, additional, Balassanian, Ronald, additional, Klein, Molly E., additional, Shad, Sonal, additional, Venters, Sara J., additional, Borowsky, Alexander D., additional, Symmans, W. Fraser, additional, and Ocal, I. Tolgay, additional

Published
2022
Full Text
View/download PDF

22. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

Author

Yau, Christina, primary, Osdoit, Marie, additional, van der Noordaa, Marieke, additional, Shad, Sonal, additional, Wei, Jane, additional, de Croze, Diane, additional, Hamy, Anne-Sophie, additional, Laé, Marick, additional, Reyal, Fabien, additional, Sonke, Gabe S, additional, Steenbruggen, Tessa G, additional, van Seijen, Maartje, additional, Wesseling, Jelle, additional, Martín, Miguel, additional, del Monte-Millán, Maria, additional, López-Tarruella, Sara, additional, Boughey, Judy C, additional, Goetz, Matthew P, additional, Hoskin, Tanya, additional, Gould, Rebekah, additional, Valero, Vicente, additional, Edge, Stephen B, additional, Abraham, Jean E, additional, Bartlett, John M S, additional, Caldas, Carlos, additional, Dunn, Janet, additional, Earl, Helena, additional, Hayward, Larry, additional, Hiller, Louise, additional, Provenzano, Elena, additional, Sammut, Stephen-John, additional, Thomas, Jeremy S, additional, Cameron, David, additional, Graham, Ashley, additional, Hall, Peter, additional, Mackintosh, Lorna, additional, Fan, Fang, additional, Godwin, Andrew K, additional, Schwensen, Kelsey, additional, Sharma, Priyanka, additional, DeMichele, Angela M, additional, Cole, Kimberly, additional, Pusztai, Lajos, additional, Kim, Mi-Ok, additional, van 't Veer, Laura J, additional, Esserman, Laura J, additional, Symmans, W Fraser, additional, Adamson, Kathi, additional, Albain, Kathy S., additional, Asare, Adam L., additional, Asare, Smita M., additional, Balassanian, Ron, additional, Beckwith, Heather, additional, Berry, Scott M., additional, Berry, Donald A., additional, Boughey, Judy C., additional, Buxton, Meredith B., additional, Chen, Yunn-Yi, additional, Chen, Beiyun, additional, Chien, A. Jo, additional, Chui, Stephen Y., additional, Clark, Amy S., additional, Clennell, Julia L., additional, Datnow, Brian, additional, DeMichele, Angela M., additional, Duan, Xiuzhen, additional, Edmiston, Kirsten K., additional, Elias, Anthony D., additional, Ellis, Erin D., additional, Esserman, Laura L., additional, Euhus, David M., additional, Fadare, Oluwole, additional, Feldman, Michael D, additional, Forero-Torres, Andres, additional, Haley, Barbara B., additional, Han, Hyo S., additional, Harada, Shuko, additional, Haugen, Patricia, additional, Helsten, Teresa, additional, Hirst, Gillian L., additional, Hylton, Nola M., additional, Isaacs, Claudine, additional, Kemmer, Kathleen, additional, Khan, Qamar J., additional, Khazai, Laila, additional, Klein, Molly E., additional, Krings, Gregor, additional, Lang, Julie E., additional, LeBeau, Lauren G., additional, Leyland-Jones, Brian, additional, Liu, Minetta C., additional, Lo, Shelly, additional, Lu, Janice, additional, Magliocco, Anthony, additional, Matthews, Jeffrey B., additional, Melisko, Michelle E., additional, Mhawech-Fauceglia, Paulette, additional, Moulder, Stacy L., additional, Murthy, Rashmi K., additional, Nanda, Rita, additional, Northfelt, Donald W., additional, Ocal, Idris T., additional, Olopade, Olufunmilayo, additional, Pambuccian, Stefan, additional, Paoloni, Melissa, additional, Park, John W., additional, Parker, Barbara A., additional, Perlmutter, Jane, additional, Peterson, Garry, additional, Rendi, Mara, additional, Rugo, Hope S., additional, Sahoo, Sunati, additional, Sams, Sharon, additional, Sanil, Ashish, additional, Sattar, Husain, additional, Schwab, Richard B., additional, Singhrao, Ruby, additional, Steeg, Katherine, additional, Stringer-Reasor, Erica, additional, Symmans, W. Fraser, additional, Tawfik, Ossama, additional, Tripathy, Debasish, additional, Troxell, Megan L., additional, van't Veer, Laura J., additional, Venters, Sara J., additional, Vinh, Tuyethoa, additional, Viscusi, Rebecca K., additional, Wallace, Anne M., additional, Wei, Shi, additional, Wilson, Amy, additional, Yau, Christina, additional, Yee, Douglas, additional, and Zeck, Jay C., additional

Published
2022
Full Text
View/download PDF

25. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer

Author

Symmans, W. Fraser, primary, Yau, Christina, additional, Chen, Yunn-Yi, additional, Balassanian, Ron, additional, Klein, Molly E., additional, Pusztai, Lajos, additional, Nanda, Rita, additional, Parker, Barbara A., additional, Datnow, Brian, additional, Krings, Gregor, additional, Wei, Shi, additional, Feldman, Michael D., additional, Duan, Xiuzhen, additional, Chen, Beiyun, additional, Sattar, Husain, additional, Khazai, Laila, additional, Zeck, Jay C., additional, Sams, Sharon, additional, Mhawech-Fauceglia, Paulette, additional, Rendi, Mara, additional, Sahoo, Sunati, additional, Ocal, Idris Tolgay, additional, Fan, Fang, additional, LeBeau, Lauren Grasso, additional, Vinh, Tuyethoa, additional, Troxell, Megan L., additional, Chien, A. Jo, additional, Wallace, Anne M., additional, Forero-Torres, Andres, additional, Ellis, Erin, additional, Albain, Kathy S., additional, Murthy, Rashmi K., additional, Boughey, Judy C., additional, Liu, Minetta C., additional, Haley, Barbara B., additional, Elias, Anthony D., additional, Clark, Amy S., additional, Kemmer, Kathleen, additional, Isaacs, Claudine, additional, Lang, Julie E., additional, Han, Hyo S., additional, Edmiston, Kirsten, additional, Viscusi, Rebecca K., additional, Northfelt, Donald W., additional, Khan, Qamar J., additional, Leyland-Jones, Brian, additional, Venters, Sara J., additional, Shad, Sonal, additional, Matthews, Jeffrey B., additional, Asare, Smita M., additional, Buxton, Meredith, additional, Asare, Adam L., additional, Rugo, Hope S., additional, Schwab, Richard B., additional, Helsten, Teresa, additional, Hylton, Nola M., additional, van ’t Veer, Laura, additional, Perlmutter, Jane, additional, DeMichele, Angela M., additional, Yee, Douglas, additional, Berry, Donald A., additional, and Esserman, Laura J., additional

Published
2021
Full Text
View/download PDF

27. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)

Author

Perez, Edith A., Press, Michael F., Dueck, Amylou C., Jenkins, Robert B., Kim, Chungyeul, Chen, Beiyun, Villalobos, Ivonne, Paik, Soonmyung, Buyse, Marc, Wiktor, Anne E., Meyer, Reid, Finnigan, Melanie, Zujewski, JoAnne, Shing, Mona, Stern, Howard M., Lingle, Wilma L., Reinholz, Monica M., and Slamon, Dennis J.

Published
2013
Full Text
View/download PDF

29. Detailed Reanalysis of 500 Breast Cancers With Equivocal HER2 Immunohistochemistry and Borderline ERBB2 Fluorescence In Situ Hybridization Results

Author

Geiersbach, Katherine B, primary, Sill, Daniel R, additional, Del Rosario, Kristina M, additional, Meyer, Reid G, additional, Spears, Grant M, additional, Yuhas, Jason A, additional, Sukov, William R, additional, Jenkins, Robert B, additional, Ocal, Idris T, additional, Mounajjed, Taofic, additional, and Chen, Beiyun, additional

Published
2021
Full Text
View/download PDF

31. Update on Immunohistochemical Analysis in Breast Lesions

Author

Peng, Yan, Butt, Yasmeen M., Chen, Beiyun, Zhang, Xinmin, and Tang, Ping

Subjects
Tumor proteins -- Analysis -- Health aspects, Immunohistochemistry -- Analysis -- Health aspects, Estrogens -- Analysis -- Health aspects, Cancer metastasis -- Analysis -- Health aspects, Health
Abstract

Context.--The utility of immunohistochemistry (IHC) in breast lesions needs to be updated with exceptions among these lesions. Biomarker studies with IHC in triple-negative breast carcinoma may help develop targeted therapies for this aggressive breast cancer. The distinction of metastatic lung adenocarcinoma to the breast and invasive breast carcinoma has significant prognostic and therapeutic implications. The determination can be challenging because both primary tumors can express estrogen receptor and/or HER2 by IHC, creating a diagnostic dilemma. Objectives.--To provide a practical update on the use of IHC markers in differential diagnoses in breast lesions, including benign, atypical, precancerous, and malignant tumors; to highlight recently published research findings on novel IHC markers in triple-negative breast carcinoma cases; and to reinforce the importance of IHC use as an ancillary tool in distinguishing metastatic lung adenocarcinoma to the breast from primary breast carcinoma using real case examples. Data Sources.--PubMed (US National Library of Medicine, Bethesda, Maryland) literature review and authors' research data and personal experiences were used in this review. Conclusions.--Immunohistochemistry has an important role in making differential diagnoses in breast lesions in morphologically equivocal settings; recognizing IHC expression status in the exceptions among these lesions will aid in the correct diagnosis of challenging breast cases. Studies suggest that androgen receptor, p16, p53, GATA3, and PELP1 may have potential diagnostic, prognostic, and predictive value in triple-negative breast carcinoma cases; these findings may provide insight and a greater understanding of the tumor biology in triple-negative breast carcinomas. In distinguishing metastatic estrogen receptor-positive or [HER2.sup.+] lung adenocarcinoma to the breast from primary breast carcinoma, napsin A, TTF-1, and GATA3 comprise a useful IHC panel. (Arch Pathol Lab Med. 2017; 141:1033-1051; doi: 10.5858/arpa.2016-0482-RA), DIFFERENTIAL DIAGNOSIS IN NONPAPILLARY AND PAPILLARY BREAST LESIONS BY IMMUNOHISTOCHEMISTRY Distinguishing Between Usual Ductal Hyperplasia and Atypical Ductal Hyperplasia/Low-Grade Ductal Carcinoma In Situ Usual ductal hyperplasia (UDH) and atypical ductal [...]

Published
2017
Full Text
View/download PDF

45. Pan-TRK Immunohistochemistry

Author

Harrison, Beth T., primary, Fowler, Elizabeth, additional, Krings, Gregor, additional, Chen, Yunn-Yi, additional, Bean, Gregory R., additional, Vincent-Salomon, Anne, additional, Fuhrmann, Laetitia, additional, Barnick, Sandra E., additional, Chen, Beiyun, additional, Hosfield, Elizabeth M., additional, Hornick, Jason L., additional, and Schnitt, Stuart J., additional

Published
2019
Full Text
View/download PDF

46. Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform

Author

Cunningham Julie M, Jenkins Robert B, Wickham-Garcia Eliza, April Craig S, Chen Beiyun, Dueck Amylou C, McCullough Ann E, Oberg Ann L, Zschunke Michael A, Asmann Yan W, Anderson S Keith, Eckel-Passow Jeanette E, Reinholz Monica M, Jen Jin, Perez Edith A, Fan Jian-Bing, and Lingle Wilma L

Subjects
Internal medicine, RC31-1245, Genetics, QH426-470
Abstract

Abstract Background The cDNA-mediated Annealing, extension, Selection and Ligation (DASL) assay has become a suitable gene expression profiling system for degraded RNA from paraffin-embedded tissue. We examined assay characteristics and the performance of the DASL 502-gene Cancer Panelv1 (1.5K) and 24,526-gene panel (24K) platforms at differentiating nine human epidermal growth factor receptor 2- positive (HER2+) and 11 HER2-negative (HER2-) paraffin-embedded breast tumors. Methods Bland-Altman plots and Spearman correlations evaluated intra/inter-panel agreement of normalized expression values. Unequal-variance t-statistics tested for differences in expression levels between HER2 + and HER2 - tumors. Regulatory network analysis was performed using Metacore (GeneGo Inc., St. Joseph, MI). Results Technical replicate correlations ranged between 0.815-0.956 and 0.986-0.997 for the 1.5K and 24K panels, respectively. Inter-panel correlations of expression values for the common 498 genes across the two panels ranged between 0.485-0.573. Inter-panel correlations of expression values of 17 probes with base-pair sequence matches between the 1.5K and 24K panels ranged between 0.652-0.899. In both panels, erythroblastic leukemia viral oncogene homolog 2 (ERBB2) was the most differentially expressed gene between the HER2 + and HER2 - tumors and seven additional genes had p-values < 0.05 and log2 -fold changes > |0.5| in expression between HER2 + and HER2 - tumors: topoisomerase II alpha (TOP2A), cyclin a2 (CCNA2), v-fos fbj murine osteosarcoma viral oncogene homolog (FOS), wingless-type mmtv integration site family, member 5a (WNT5A), growth factor receptor-bound protein 7 (GRB7), cell division cycle 2 (CDC2), and baculoviral iap repeat-containing protein 5 (BIRC5). The top 52 discriminating probes from the 24K panel are enriched with genes belonging to the regulatory networks centered around v-myc avian myelocytomatosis viral oncogene homolog (MYC), tumor protein p53 (TP53), and estrogen receptor α (ESR1). Network analysis with a two-step extension also showed that the eight discriminating genes common to the 1.5K and 24K panels are functionally linked together through MYC, TP53, and ESR1. Conclusions The relative RNA abundance obtained from two highly differing density gene panels are correlated with eight common genes differentiating HER2 + and HER2 - breast tumors. Network analyses demonstrated biological consistency between the 1.5K and 24K gene panels.

Published
2010
Full Text
View/download PDF

48. Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial

Author

Yee, Douglas, DeMichele, Angela M., Yau, Christina, Isaacs, Claudine, Symmans, W. Fraser, Albain, Kathy S., Chen, Yunn-Yi, Krings, Gregor, Wei, Shi, Harada, Shuko, Datnow, Brian, Fadare, Oluwole, Klein, Molly, Pambuccian, Stefan, Chen, Beiyun, Adamson, Kathi, Sams, Sharon, Mhawech-Fauceglia, Paulette, Magliocco, Anthony, and Feldman, Mike

Published
2020
Full Text
View/download PDF

49. Ability of Intraoperative Pathologic Analysis of Ductal Carcinoma In Situ to Guide Selective Use of Sentinel Lymph Node Surgery

Author

Murphy, Brittany L., primary, Gonzalez, Alexandra B., additional, Keeney, Michael G., additional, Chen, Beiyun, additional, Conners, Amy L., additional, Henrichsen, Tara L., additional, Degnim, Amy C., additional, Harmsen, William S., additional, Boughey, Judy C., additional, Hieken, Tina J., additional, Habermann, Elizabeth B., additional, and Jakub, James W., additional

Published
2018
Full Text
View/download PDF

50. IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2+ Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831

Author

Reinholz, Monica M., primary, Chen, Beiyun, additional, Dueck, Amylou C., additional, Tenner, Kathleen, additional, Ballman, Karla, additional, Riehle, Darren, additional, Jenkins, Robert B., additional, Geiger, Xochiquetzal J., additional, McCullough, Ann E., additional, and Perez, Edith A., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results